In 2011, Alkion BioPharma has been created to revolutionise the secondary metabolims production for cancer therapies.
Imperial Innovations, a team of Imperial College researchers & business professionals joined together to develop the technologies able to transform the non-GMO plants into a natural biorefinery.
Quickly the technological platform received strong interests from the cosmetic community and the company signed research contracts to develop new disruptive cosmetic ingredients.
Four years after inception, with a strong commercial pipeline, Alkion BioPharma has been acquired by Evonik Industries AG for cosmetic & food supplements applications.
The new company Alkion BioInnovations was created in march 2017 in order to develop disruptive nutrition & pharmaceutical solutions. The company owns exclusive rights on this applications.